Edition:
United States

Jazz Pharmaceuticals PLC (JAZZ.O)

JAZZ.O on Nasdaq

134.55USD
1:50pm EST
Change (% chg)

$-2.64 (-1.92%)
Prev Close
$137.19
Open
$138.03
Day's High
$138.66
Day's Low
$134.35
Volume
339,516
Avg. Vol
641,449
52-wk High
$160.00
52-wk Low
$95.80

JAZZ.O

Chart for JAZZ.O

About

Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead... (more)

Overall

Beta: 1.22
Market Cap(Mil.): $8,216.63
Shares Outstanding(Mil.): 59.89
Dividend: --
Yield (%): --

Financials

  JAZZ.O Industry Sector
P/E (TTM): 24.00 28.39 29.32
EPS (TTM): 5.72 -- --
ROI: 9.09 13.54 13.03
ROE: 21.67 14.43 14.17

BRIEF-Jazz Pharmaceuticals announces first patient enrolled in phase 2 clinical study evaluating JZP-110 for excessive sleepiness in Parkinson's disease

* Jazz Pharmaceuticals announces first patient enrolled in Phase 2 clinical study evaluating JZP-110 for excessive sleepiness in Parkinson's disease

Feb 08 2017

BRIEF-Jazz Pharmaceuticals comments on FDA nod for generic version of Xyrem

* Jazz Pharmaceuticals says it will evaluate FDA's waiver of requirement for a single, shared system rems in connection with approval of a generic version of Xyrem

Jan 18 2017

FDA approves generic version of Jazz Pharma's sleep disorder drug

The U.S. Food and Drug Administration said it had approved the first generic version of Xyrem, Jazz Pharmaceuticals Plc's drug to treat patients with narcolepsy, a kind of sleeping disorder.

Jan 17 2017

UPDATE 1-FDA approves generic version of Jazz Pharma's sleep disorder drug

Jan 17 The U.S. Food and Drug Administration said it had approved the first generic version of Xyrem, Jazz Pharmaceuticals Plc's drug to treat patients with narcolepsy, a kind of sleeping disorder.

Jan 17 2017

FDA approves generic version of Jazz Pharma's sleep disorder drug

Jan 17 The U.S. Food and Drug Administration said on Tuesday it had approved the first generic version of Xyrem, Jazz Pharmaceuticals Plc's drug to treat patients with a medical condition that causes excessive daytime sleepiness. (http://bit.ly/2jHzIS9)

Jan 17 2017

BRIEF-Jazz Pharmaceuticals posts Q3 adj. earnings $2.57/shr

* Jazz Pharmaceuticals announces third quarter 2016 financial results

Nov 08 2016

BRIEF-Jazz pharmaceuticals plc - initiates rolling nda submission

* Expects to complete submission of NDA by early 2017, and will request a priority review.

Oct 03 2016

More From Around the Web

Earnings vs. Estimates